Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.
about
Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatmentGuidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of CardiologyEnoxaparin in acute coronary syndromesClinical application of enoxaparin.Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.Safety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registryPlatelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease.Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome.Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction.The role of low-molecular-weight heparins in cardiovascular medicine.Optimizing adjunctive antithrombotic therapy in the treatment of acute myocardial infarction: a role for low-molecular-weight heparin.Low-molecular-weight heparins in the cardiac catheterization laboratoryConsiderations in combination therapy: fibrinolytics plus glycoprotein IIb/IIIa receptor inhibitors in acute myocardial infarction.Facilitated percutaneous coronary intervention in acute myocardial infarction: attractive concept but difficult to prove!Evolving role of low-molecular-weight heparins in ST-elevation myocardial infarction.Low-molecular-weight heparin in patients with acute ST-segment elevation myocardial infarction.Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.Overview of contemporary reperfusion strategies in acute ST-elevation myocardial infarction.Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature.Utilizing enoxaparin in the management of STEMI.Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction.New anticoagulant strategies in ST elevation myocardial infarction: trials and clinical implicationsEfficacy and Safety of Low-Molecular-Weight Heparins As An Adjunct to Thrombolysis in Acute ST-Elevation Myocardial Infarction.Safety evaluation of enoxaparin in currently approved indications.Enoxaparin: a pharmacologic and clinical review.Cost effectiveness of anticoagulation in acute coronary syndromes.Combination of enoxaparin and fibroblast growth factor-1 increases myocardial blood flow and capillary density after myocardial infarction in rabbits.Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis.High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.Low-Molecular-Weight Heparin in Acute Coronary Syndromes
P2860
Q28217792-12D50D62-E483-4D3C-A114-E5E49BA7F50CQ28239975-44BB9012-188E-4D01-BB70-B2C9E9EF1802Q28301431-42D89E3B-2DB2-4553-BA0E-A30C80B8AE0CQ33360866-800D3B7E-8696-4164-8E85-265781D84D02Q33360869-AAA8ECDB-DED1-4473-BA3E-846A1BFD340AQ34196711-493743DF-9E7B-4510-8744-715FE4FAF0CEQ35001049-0A6DF835-1187-4FD0-AB7A-017E4BFAE0D8Q35139249-B5CF5311-090B-4E45-948A-87D14C7D89E3Q35582491-0DE60D6E-E110-4244-8AB9-4861C5828FF2Q35591215-78E3B4AE-248F-44BC-93BE-9417106371C3Q35638777-E09A3053-9CF2-4D78-9437-55FDAAC8CC4EQ35733959-C24208B3-3DC1-4D92-90C2-1CCEBF59DC8AQ35857484-646FBD66-542D-44B7-80F1-B4C5121C7D1FQ35945662-B7F2998F-2617-4F28-AEC5-75BBCB4FAF76Q36035257-BB634C83-7DC2-4342-BB0C-61A456C96A5EQ36110453-5CA7B9F2-943D-40A9-8B1C-9F775C9E6F5EQ36131116-ABA459FC-1A5D-43CC-91F8-39EACD7887EEQ36216834-B32E74EE-D2FC-4EBF-93F1-DA828129E2AFQ36545687-0BCBB124-5859-4EE3-803D-CDA39A576686Q37031371-2CAD008F-08DA-454F-8FA1-3810569618A7Q37167513-B62623AE-0827-497A-87F0-B5FF96F1B008Q37193906-F217F878-991E-4E2C-BD2F-B0784587CD6EQ37414802-0B9ECCAA-444D-4715-8F5C-573A2E5A05C0Q37622250-0D498F49-F516-43E1-94DD-3DE4FB58127DQ37862264-B5159CF7-82EF-46AA-BDB6-B261FDDB5E04Q37992680-66454EC5-F0E2-4188-BC8C-4FF9BF694BC8Q40356071-8D43BB6C-4D34-4B69-8195-ED9BE3324153Q44517148-E1ED92F0-BEA0-4C77-89A2-CCAE9225672BQ50665407-FFBDC587-45D7-4EBE-8ECD-ADE1A4E78B56Q53529884-65F545C8-7A32-4BFD-997A-DB51F2D60BDCQ57243775-8300DB9A-D6F4-4550-912F-4ACF665EDAD8
P2860
Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Enoxaparin as adjunctive antit ...... al Infarction (TIMI) 23 Trial.
@en
Enoxaparin as adjunctive antit ...... lysis in Myocardial Infarction
@nl
type
label
Enoxaparin as adjunctive antit ...... al Infarction (TIMI) 23 Trial.
@en
Enoxaparin as adjunctive antit ...... lysis in Myocardial Infarction
@nl
prefLabel
Enoxaparin as adjunctive antit ...... al Infarction (TIMI) 23 Trial.
@en
Enoxaparin as adjunctive antit ...... lysis in Myocardial Infarction
@nl
P2093
P50
P1433
P1476
Enoxaparin as adjunctive antit ...... al Infarction (TIMI) 23 Trial.
@en
P2093
C Michael Gibson
Frederique Bigonzi
Ghislaine Pisapia
Hans W Louwerenburg
Hein Heidbuchel
Hubert F Baars
Jan C L Wesdorp
P304
P356
10.1161/01.CIR.0000013402.34759.46
P407
P577
2002-04-01T00:00:00Z